• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

AMAG Pharmaceuticals

edit

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which utilizes the technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company manufactures and sells two approved products, Feraheme (ferumoxytol) Injection for intravenous (IV) and GastroMARK. On June 30, 2009, Feraheme was approved for marketing in the United States by the United States Food and Drug Administration (FDA), for use as an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).

Recent Milestones

edit

• 
  AMAG Pharmaceuticals — AMAG gets European approval, $15M milestone payment (6/22/12)
  Posted 6/22/12 at 6:25pm via masshightech.com
• 
  Went public with stock symbol NASDAQ:AMAG.
  Posted 5/26/11 at 5:44pm
• 
  AMAG Pharmaceuticals added Brian J.G. Pereira as President and CEO.
  Posted 5/26/11 at 5:43pm

Videos

Screenshots

edit

Stock Price

Sources

AMAG gets European approval, $15M milestone payment (masshightech.com) [edit]